Sex difference in risk of torsade de pointes with d,l-sotalol.
about
Methodological considerations in the design of trials for safety assessment of new drugs and chemical entitiesFemale-specific aspects in the pharmacotherapy of chronic cardiovascular diseasesEffects of 17beta-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmiaAcute effects of sex steroid hormones on susceptibility to cardiac arrhythmias: a simulation studyDifferences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella reviewAtrial fibrillation in women: treatmentMeta-analysis of the Risk of Torsades de Pointes in patients treated with intravenous racemic sotalol.Focal atrial tachycardia: reanalysis of the clinical and electrophysiologic characteristics and prediction of successful radiofrequency ablation.Adrenal adenoma presenting with torsade de pointes--a case report.Risk of recurrent cardiac events after onset of menopause in women with congenital long-QT syndrome types 1 and 2Genotype-specific risk stratification and management of patients with long QT syndrome.Gender and cardiac arrhythmias.Optimal management with Class I and Class III antiarrhythmic drugs should be done in the outpatient setting: protagonist.Influence of sex hormones and phytoestrogens on heart disease in men and womenMacrolide antibiotics and the risk of cardiac arrhythmiasElectrophysiological remodeling in heart failureA multiscale computational modelling approach predicts mechanisms of female sex risk in the setting of arousal-induced arrhythmias.Drug-induced QT interval prolongation: mechanisms and clinical managementProarrhythmia, a serious complication of antiarrhythmic drugs.Who develops severe or fatal adverse drug reactions to selective serotonin reuptake inhibitors?Gender differences in arrhythmias.Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockersClinical relevance and management of drug-related QT interval prolongation.Atrial fibrillation in patients with congestive heart failure.Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalolSex-steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of AtherosclerosisCardiac risks associated with antibiotics: azithromycin and levofloxacinChronic arsenic exposure and cardiac repolarization abnormalities with QT interval prolongation in a population-based study.Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine.Assessment of the effect of a single oral dose of telithromycin on sotalol-induced qt interval prolongation in healthy womenDrugs that cause Torsades de pointes and increase the risk of sudden cardiac death.Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervalsBlinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias.A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.Blockade of I(Ca) suppresses early afterdepolarizations and reduces transmural dispersion of repolarization in a whole heart model of chronic heart failureIn silico Prediction of Sex-Based Differences in Human Susceptibility to Cardiac Ventricular TachyarrhythmiasGender disparities in torsade de pointes ventricular tachycardia.Therapeutic implications of the gender-specific aspects of cardiovascular disease.Electrocardiographic Predictors of Torsadogenic Risk During Dofetilide or Sotalol Initiation: Utility of a Novel T Wave Analysis Program.
P2860
Q24807158-F81E247C-5300-406F-9144-84E9488F8D5CQ28182631-60471F7D-A236-4143-A114-A16CDDAAEDDBQ28377348-C6B02ACE-F358-4897-AA44-93A3B6042FECQ28472692-F88DEBDC-CCAB-4B44-A1F7-2FE8C493243BQ28474985-DC7B0982-D6D9-4F9A-94AA-669F3CA0A2C1Q30241862-EDFCD09F-AACC-4682-A60D-AD793ADB6174Q31827349-1ED783EC-1E3E-41B2-91ED-CCD1882B7C44Q32064407-50538DB8-45A8-4D98-93AE-B1339A6402A1Q33147935-54D589CD-267F-4149-985D-776D9A2140CBQ33160103-503EB48B-C25A-40BE-9904-F5BF9CB30439Q33163507-258C9BAB-3754-4D66-A253-F04A58555698Q33583449-36677AA9-7DB9-4487-AB71-074BD3140BCBQ33598017-A10348DA-5E25-472B-B454-6A4FFE023D7CQ33721061-FD4645AD-6A17-40C4-B9DC-2C6FBE0D8D45Q33772270-397989D9-6B80-43D0-8DBB-C48C6CFE3483Q33887264-75ED72BF-F076-478E-AE57-466CA5F2F06FQ33903321-800A62FB-A17D-4B10-B7C2-28BFBC4C169AQ33949538-FF33F874-DFEC-4E4C-9D28-996F301A05BCQ34027347-A61E6B7E-D42E-4DD8-9E5A-A7A42E677BB6Q34230358-E4B519BF-5B66-437E-990A-8392DFA0CA7AQ34527293-5050EC31-DDE3-4169-8C17-E5D78D11CCEDQ35110915-64D4D73A-6BA6-451B-AC1E-2A5CB112D6CBQ35186542-AA1371FF-F5CD-43DE-8A2D-61FF2E246E24Q35197762-234EB336-6E91-49CD-A7B5-84863B06526EQ35211438-A3341B2F-9D26-4869-A5B3-65DCA37DFB27Q35450727-FDF3D894-E882-4268-A7BA-5954CA803812Q35502601-9F0C6D0D-E7DA-4C12-8C8D-254A40FC9F44Q35790980-DEB4ED57-782E-4E81-BF51-0F0F88723BC4Q35825448-8ADC6095-481A-4809-8DF9-E0821CC4BC00Q35827140-6B60F5BD-DCC7-4E61-A413-3D11812F3129Q35860954-F3D61199-5B0A-4805-AEC2-ABBA46BFEF9BQ35892164-FE5F58F7-E984-428C-99F2-707B7EFDEECAQ35904744-1AC2C56F-2BD3-4100-A2E4-EDC6915E696EQ35955904-968595A0-59FA-45E2-8753-06BF2AF81FCDQ36054477-BE809EB4-E3AB-42E1-8987-3E5CA3B3A989Q36159158-5331BB19-48F1-4C45-8341-635FC5D75596Q36234352-F224D533-630A-48D1-8F1C-2F325CF075CCQ36404376-8EF2FD08-2A86-455E-B4E3-43736A0BDF3BQ36467824-4FBBBC63-0880-4E9E-A5ED-A42A21CC454AQ36514742-B537D625-5C0E-429B-AA2C-2676FC19BF8C
P2860
Sex difference in risk of torsade de pointes with d,l-sotalol.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Sex difference in risk of torsade de pointes with d,l-sotalol.
@en
Sex difference in risk of torsade de pointes with d,l-sotalol.
@nl
type
label
Sex difference in risk of torsade de pointes with d,l-sotalol.
@en
Sex difference in risk of torsade de pointes with d,l-sotalol.
@nl
prefLabel
Sex difference in risk of torsade de pointes with d,l-sotalol.
@en
Sex difference in risk of torsade de pointes with d,l-sotalol.
@nl
P2093
P1433
P1476
Sex difference in risk of torsade de pointes with d,l-sotalol.
@en
P2093
P304
P356
10.1161/01.CIR.94.10.2535
P407
P577
1996-11-01T00:00:00Z